标题
Camrelizumab: First Global Approval
作者
关键词
-
出版物
DRUGS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-07-16
DOI
10.1007/s40265-019-01167-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.
- (2019) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
- (2019) Jing Nie et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
- (2018) Hongnan Mo et al. BRITISH JOURNAL OF CANCER
- Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
- (2018) Jing Huang et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
- (2018) Wenying Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients.
- (2018) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment
- (2018) S K Qin et al. ANNALS OF ONCOLOGY
- 1505TiPA phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer
- (2018) F Wu et al. ANNALS OF ONCOLOGY
- Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China
- (2018) Jing Huang et al. CANCER
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Safety and Effect of Radiation Therapy Combined with Anti-PD-1 Antibody SHR-1210 as First-Line Treatment on Patients with Intolerable Concurrent Chemoradiotherapy Esophageal Cancer: A Phase 1B Clinical Trial
- (2018) Q. Pang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients with Esophageal Squamous Cell Cancer
- (2018) Z. Jing et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started